Business
OWC Pharmaceutical Research Corp Appoints Dr. Sharon Rozenblat Senior Advisor to Scientific Advisory Board of its Wholly-Owned Subsidiary
OWC Pharmaceutical Research Corp Appoints Dr. Sharon Rozenblat Senior Advisor to Scientific Advisory Board of its Wholly-Owned Subsidiary.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp Appoints Dr. Sharon Rozenblat Senior Advisor to Scientific Advisory Board of its Wholly-Owned Subsidiary\n\n\n\n\n\nOWC Pharmaceutical Research Corp Appoints Dr. Sharon Rozenblat Senior Advisor to Scientific Advisory Board of its Wholly-Owned Subsidiary\nDr. Rozenblat is an Expert in Biopharmaceutical Formulation for Skin Diseases and Cosmetics\nPR Newswire\nPETACH TIKVA, Israel, February 7, 2017\n\n\n\nPETACH TIKVA, Israel, February 7, 2017 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTCQB: OWCP), (\"OWC\" or the \"Company\"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Sharon Rozenblat as Senior Advisor to the Scientific Advisory Board of its wholly-owned Israeli subsidiary, One World Cannabis Ltd (\"OWC Israel\").\n\n     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg)\n\n\nDr. Rozenblat will be tasked with overseeing the completion of the pre-clinical safety studies on the Company's treatment for psoriasis, which commenced in November 2016. Dr. Rozenblat will also steer the Company's efforts to commercialize OWC's cannabis-based formulations and delivery mechanisms.\n\nDr. Yehuda Baruch, OWC's Chief Scientific Officer, commented on the appointment, \"Dr. Rozenblat has had a significant impact in the field of dermatology, specifically with regard to botanical formulations. With more than 15 years' experience in the research and development of herbal extracts and related products, as well as considerable experience in the design and management of clinical trials, she is the perfect complement to our scientific team.\"\n\nFrom 2007 to 2015, Dr. Rozenblat served as Chief Scientist at Kamedis ltd., an Israeli-based dermatological company, where she had established and managed the research and development of herbal products for the treatment of dermatological conditions.\n\nIn addition to her work at Kamedis, Dr. Rozenblat serves as a consultant to international organizations, including as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial Research and Development Foundation (KORIL), and the Israel-Singapore Foundation (SIIRD), both of which resulted in numerous products and patents. Dr. Rozenblat was...